Lunaphore Technologies SA, Lausanne, Switzerland, a medtech firm developing equipment for cancer research and tissue diagnostics, has announced the release of its first product, the LabSat automated reagent delivery system for immunohistochemistry (IHC) staining .
The CE-marked instrument complies with all applicable product health, safety, and environmental regulations of the European Union and will be available in most European countries.
The LabSat system consists of a single-slide, automated reagent delivery system that can perform IHC staining on tissue samples within 10 to 30 minutes. The speed of the device is achieved by a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation. The patented technology enables high-precision tissue staining, with a significant reduction in reagent incubation times.
Ata Tuna Ciftlik, Lunaphore.
“This very first product aims to bring our breakthrough technology to the hands of our customers,” says Ata Tuna Ciftlik, PhD, founder and CEO of Lunaphore. “We believe that its precision and speed will open a multitude of staining possibilities for users. In parallel, we’re working on the next product iterations to answer the needs of customers with greater needs of automation as well as a wider portfolio of applications.”
The company is also developing a solution for the in vitro diagnostics field, which it aims to launch in the near future.
For further information, visit Lunaphore.
